BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR

Vishruti Makani1, Yong-gil Jang1, Kevin Christopher1, Wesley Judy1, Jacob Eckstein1, Kenneth Hensley2, Nicolas Chiaia1, Dong-Shik Kim3, Joshua Park1*

1 Department of Neurosciences, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America, 2 Department of Pathology, College of Medicine and Life Sciences, University of Toledo, Toledo, Ohio, United States of America, 3 Department of Chemical Engineering, College of Engineering, University of Toledo, Toledo, Ohio, United States of America

* Joshua.park2@utoledo.edu

Abstract

An enormous amount of efforts have been poured to find an effective therapeutic agent for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD). Among those, neurotrophic peptides that regenerate neuronal structures and increase neuron survival show a promise in slowing neurodegeneration. However, the short plasma half-life and poor blood-brain-barrier (BBB)-permeability of neurotrophic peptides limit their in vivo efficacy. Thus, an alternative neurotrophic agent that has longer plasma half-life and better BBB-permeability has been sought for. Based on the recent findings of neuroprotective polysaccharides, we searched for a BBB-permeable neuroprotective polysaccharide among natural polysaccharides that are approved for human use. Then, we discovered midi-GAGR, a BBB-permeable, long plasma half-life, strong neuroprotective and neurotrophic polysaccharide. Midi-GAGR is a 4.7kD cleavage product of low acyl gellan gum that is approved by FDA for human use. Midi-GAGR protected rodent cortical neurons not only from the pathological concentrations of co-/post-treated free reactive radicals and Aβ42 peptide but also from activated microglial cells. Moreover, midi-GAGR showed a good neurotrophic effect; it enhanced neurite outgrowth and increased phosphorylated cAMP-responsive element binding protein (pCREB) in the nuclei of primary cortical neurons. Furthermore, intra-nasally administered midi-GAGR penetrated the BBB and exerted its neurotrophic effect inside the brain for 24 h after one-time administration. Midi-GAGR appears to activate fibroblast growth factor receptor 1 (FGFR1) and its downstream neurotrophic signaling pathway for neuroprotection and CREB activation. Additionally, 14-day intranasal administration of midi-GAGR not only increased neuronal activity markers but also decreased hyperphosphorylated tau, a precursor of neurofibrillary tangle, in the brains of the AD mouse model, 3xTg-AD. Taken together, midi-GAGR with good BBB-permeability, long plasma half-life, and strong neuroprotective and neurotrophic effects has a great therapeutic potential for the treatment of neurodegenerative diseases, especially AD.
Introduction

Conventional treatments for neurodegenerative diseases address only symptoms without disease-modifying effect but with serious side effects [1–6]. Currently, there is no effective treatment for neurodegenerative diseases. As aged population grows very fast, the incidence of aging-related neurodegenerative diseases and their healthcare costs are increased exponentially. AD alone affects over 5 million people in the US and costs the US 100 billion dollars per year [7, 8]. Thus, it is of utmost urgency to find an effective treatment for neurodegenerative diseases.

Pharmacological inhibitors that are purposed to reduce pathogenic factors have been unsuccessful in exerting a disease-modifying effect [9–12]. Conversely, neurotrophic treatment that revives neurons and rebuilds synapses and neurites shows a promise in slowing neurodegeneration [8, 13–23]. Moreover, neurotrophic treatment appears to have a larger intervention window than preventive toxin-clearing approaches [24]. Thus, various neurotrophic peptides were tested regarding their efficacies in treating neurodegenerative diseases [8, 13–21, 23, 25, 26]. Brain-derived neurotrophic factor (BDNF) is one of the major targets for neurotrophic treatment [27, 28]. However, the poor BBB-permeability and short plasma half-life of neurotrophic peptides including BDNF lower their efficacy [29–33]. To overcome the limitations, viral vectors and mesenchymal stem cells that constantly produce neurotrophic peptides have been injected into the brain [34–36]. However, the invasiveness of surgical delivery, mutagenesis, and unregulated peptide production are of concern. Nanoparticles also have been tested for the intranasal delivery of neurotrophic peptide into the brain while the short plasma half-life of peptide is still a limiting factor [37–39].

Recently, a group of polysaccharides were found to have neuroprotective effects [40–43], raising the possibility of using the polysaccharides for the treatment of neurodegenerative diseases. If the polysaccharides can penetrate the BBB, those are expected to exert longer physiological effect than peptides in vivo as polysaccharides generally have long plasma half-lives [44–47]. Among the polysaccharides, however, only chitosan shows BBB-permeability [37–39, 48, 49]. All these indications prompted us to search for a BBB-permeable and neuroprotective polysaccharide among natural polysaccharides that are approved by FDA for human use. Then, we discovered a BBB-permeable, long plasma half-life, neurotrophic, and neuroprotective polysaccharide, midi-GAGR, that is a 4.7kD cleavage product of low acyl gellan gum. Low acyl gellan gum is registered as ‘Everything Added to Food in the United States (EAFUS)’ (FDA 21 CFR 172.665). Low acyl (LA) gellan gum consists of a repeating tetrasaccharide, D-Glc(β1–4)D-GlcA(β1–4)D-Glc(β1–4)L-Rha(α1–3) (called ‘LA-GAGR’ in our study, Fig 1). LA-GAGR has few side effects in human at >160 mg/kg/day [50] and in animal at >1000 mg/kg/day according to FDA report.

In addition, we found that midi-GAGR bound to FGFR1 and activated FGFR1-mediated neurotrophic signaling pathway [51–53]. FGFR1 is predominantly expressed in neurons including hippocampal and dentate gyrus neurons [54, 55] and contributes to neurite outgrowth, neuronal migration, and axonal pathfinding [56, 57]. Fibroblast growth factor 2 (FGF2), a major ligand for FGFR1 [58, 59], shows a good therapeutic potential for the treatment of neurodegenerative diseases. FGF2 enhanced survival and neurite outgrowth in hippocampal neurons in vitro [60, 61]. In animals, FGF2 reduced AD pathogenesis [62–65], improved memory [66–68], and reduced β-secretase and Aβ peptide [69, 70]. Nonetheless, the short plasma half-life and poor BBB-permeability of FGF2 lower its in vivo efficacy [67, 71]. FGFR1 can be also activated by its interaction with neural cell adhesion molecules (NCAMs) [72, 73]. Homodimeric NCAM180s interact with FGFR1 via its fibronectin type III (FN3) modules I and II and activate FGFR1 [74]. This interaction leads to the activation of two signaling pathways under FGFR1: (i) FGFR substrate 2a (FRS2a)-Shc-growth factor receptor bound...
protein 2 (Grb2)-protein kinase C (PKC)-Raf-mitogen activated protein kinase (MAPK)/extracellularly regulated kinase (ERK) pathway and (ii) phosphoinositide 3-kinase (PI3K)-Akt/phospholiase Cγ (PLCγ)-Ca2+-calmodulin kinase II (CaMKII) pathway [73, 75, 76]. Under NCAM180, fyn-focal adhesion kinase (FAK)-src-MEK-ERK pathway is activated [73]. ERK and Akt, then, phosphorylate CREB [77]. Recently, Fibroblast Growth Loop (FGL) peptide containing 15 amino acids in the 2nd FN domain of NCAM [74] was found to bind to FGFR1 and exert FGF-like effects [78]. FGL activates FGFR1 independently of NCAM [79]. FGL enhanced neuritogenesis and synaptogenesis, protected neurons from Aβ42 and 6-hydroxydopamine, improved learning and memory and synaptic transmission [52, 79–83]. In addition, Akt activated by FGL phosphorylates and inhibits glycogen synthase kinase 3β (GSK3β) [82], the kinase responsible for the hyperphosphorylation of tau (p-tau) and the formation of neurofibrillary tangles (NFTs) [84]. Although FGL shows some BBB-permeability [81] and 4-h plasma half-life [85], its peptide-ness is still a limiting factor.

Here, we present a novel alternative (midi-GAGR) to neurotrophic peptide that shows neuroprotective and neurotrophic effects, good BBB-permeability and long plasma half-life (~24 h). Our study will present solid evidence that supports the great potential of midi-GAGR for the treatment of neurodegenerative diseases.

Materials and Methods

Animals

Embryos (at the embryonic day of 17 [E17]) from female pregnant mice (BALB/C, Charles River Laboratories International Inc., Wilmington, MA) and female pregnant rats (E17, Sprague Dawley [SD], bred-in-house) were used to isolate primary cortical neurons for in vitro primary culturing. Adult female SD rats (12–16 weeks old, bred-in-house) were used for in vivo studies to examine the BBB-permeability and neurotrophic effect of midi-GAGR. 12-month-old 3xTg-AD mice (female, B6; 129-Psen1tm1Mpm Tg [APPswe, tauP301L] 1Lfa/Mmjax, Jackson Laboratory, Bar Harbor, ME) were used for the studies to examine the effects of midi-GAGR on neurotrophic and neurodegenerative markers in 3xTg-AD mouse brains. Animals were housed at room temperature under a 12-h light/dark cycle. Food and water were provided ad libitum. All experiments were performed during the light phase (7 am-7 pm). All the procedures of animal use described in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of University of Toledo College of Medicine and Life Science in accordance with National Institutes of Health guidelines.
Antibodies

Antibodies to FGFR1 (SAB4300488), neurofilament 200 (NF200, N4142), and α-tubulin (T9026), synaptophysin (S5768), and βIII-tubulin (T2200) were purchased from Sigma (St. Louis, MO). Antibodies to PSD95 (sc-32290), pCREB (P-Ser133, sc-7978), CREB (sc-377154), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, sc-32233), and growth associated protein 43 (GAP-43, sc-17790) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibody to PHF-tau (P-Ser202, AT8, MN1020B) was purchased from Thermo Scientific (Rockford, IL). Antibodies to Iba1 (ab5076) and pCREB (P-Ser133, ab30651) were purchased from Abcam Inc. (Cambridge, MA). Antibody to tau (610672) was purchased from BD Transduction Laboratories (Lexington, KY).

Hydrolysis of low acyl gellan gum

1 mL of 1% salicin solution (1 g salicin [Sigma] in 100 mL of 0.1 M acetate buffer [pH 5]) was pre-warmed at 37°C for 6–8 minutes and mixed with 2 mg of α(1→3)-glycosidase (Sigma) to make the enzyme solution for the hydrolysis of low acyl gellan gum (LA-GAGR, CPKelco Co. [Atlanta, GA]). The enzyme solution was diluted to 0.1 mg/mL before use. 0.48 g of LA-GAGR was dissolved in 80 mL of the acetate/salicin solution. 8 mL of LA-GAGR solution was mixed with 2 mL of the enzyme solution in 15 mL polypropylene corning tubes and incubated at 37°C (80 rpm) for 24, 48, or 72 h for the enzymatic digestion of LA-GAGR. Enzyme reaction was stopped by incubation in a hot water bath for 5 min and dried in a vacuum dryer (-60 cm Hg gauge) at 70°C. Dried gel pellet was then washed extensively in de-ionized water by stirring for 48 h (fresh water replaced every 12 h) to wash off salts and enzyme from the pellet and processed for viscosity measurement using a parallel plate rheometer (PPR, Rheometrics, Inc., Piscataway, NJ) equipped with rheometer software, TA Orchestrator (TA Instrument, Inc., New Castle, DE). From the viscosity-storage modulus profiles, the MW distributions of the cleavage products were determined using the RheoAnalyzer program (TomCoat Oy, Inc., Finland). The pellet was dissolved in 100 mL de-ionized water, autoclaved at 120°C for 45 min, aliquoted, and kept at -80°C until use.

Drug treatment of Neuro2A (N2A) cells

N2A cells (passage 7–10, a gift from Dr. Marthe Howard at University of Toledo [ATCC® CCL-131™]) were sparsely seeded on coverslips in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, Grand Island, NY) containing 10% heat-inactivated fetal bovine serum (FBS), 5 g/L D-glucose, 110 mg/L sodium pyruvate, and 1 x Pen Strep (Life Technologies) and incubated at 37°C in a humidified 5% CO2 incubator for 48 h. Then, serum-containing medium was replaced with serum-free medium containing vehicle (H2O) or different concentrations of midi-GAGR (0.001, 0.01, 0.1, 1, and 10 μM) and incubated for 3 days prior to immunocytochemistry using anti-α-tubulin antibody followed by secondary Alexa488nm antibody (Life Technologies) [86]. Coverslips were then mounted on glass slides using Fluoromount G (Fisher Scientific, Pittsburgh, PA). The images of cells were taken using a TCS SP5 multi-photon laser scanning confocal microscope (Leica Microsystems, Bannockburn, IL). The confocal microscope is equipped with conventional solid state, a ti-sapphire tunable multi-photon laser (Coherent, Santa Clara, CA), and acousto optical beam splitter AOBS. Images were taken with either 40 x or 20 x Zeiss alpha plan fluor oil objective (1.4 NA). Cells having the neurite length longer than 2 times the diameter of cell body were chosen for image analysis. To examine the protective effect of midi-GAGR against oxidative stress-induced neurite atrophy, differentiated N2A cells were pre-treated with midi-GAGR (0, 0.001, 0.01, 0.1, 1, and 10 μM) and then with either 4-hydroxynonenal (4HNE) (Cayman Chemical, Ann Arbor, MI)
or H₂O₂ (Sigma). First, we determined the toxic dose ranges of 4HNE and H₂O₂ that cause neurite atrophy by treating differentiated N2A cells with 0, 1, 5, 10 or 25 μM of 4HNE for 48 h or 0, 1, 10, 50, 100, or 200 μM of H₂O₂ for 24 h. Then, the doses that showed maximum inhibitory effects were used to treat differentiated N2A cells along with 0, 0.001, 0.01, 0.1, 1, and 10 μM of midi-GAGR. The total neurite lengths of N2A cells in different conditions were measured using ‘Metamorph’ software (Molecular Devices, Sunnyvale, CA) and used to calculate average total neurite lengths.

Drug treatment of primary rodent cortical neurons

We examined the protective effect of polysaccharides on primary cortical neurons from 4HNE, H₂O₂, and Aβ₄₂ peptide (Sigma) using LIVE/DEAD® Viability/Cytotoxicity Assay Kit (Life Technologies). Female pregnant mice (BALB/C, E17, Charles River Laboratories International, Inc.) or female pregnant SD rats (E17, bred in house) were anesthetized and dissected to obtain 8–9 embryos per animal. Cortical neurons were isolated from embryonic brains and differentiated on poly-L-lysine-coated coverslips in B27/neurobasal medium. For drug treatment before free radical treatment, mouse cortical neurons (5 days in vitro [DIV5]) were treated with vehicle (H₂O), 1 μM of 5kD dextran (Sigma), alginate (Sigma), midi-GAGR, 0.01 μM of high acyl gellan gum (HA-GAGR, CPKelco Co.), or 0.1 μM of LA-GAGR for 24 h and then treated with 10 μM 4HNE or 50 μM H₂O₂ for 24 h, or 2 μM Aβ₄₂ peptide for 48 h prior to viability/cytotoxicity assay. For drug co-treatment with free radicals, rat cortical neurons (DIV5) were treated with 1 μM of dextran, alginate, or midi-GAGR, 0.01 μM of HA-GAGR, or 0.1 μM of LA-GAGR along with either 10 μM 4HNE (24 h) or 2 μM Aβ₄₂ peptide (48 h). To examine the extent to which midi-GAGR-mediated neuroprotection depends on FGFR1, rat cortical neurons (E17, DIV5) were pre-treated with 4 μM SU5402 (Sigma) for 6 h and treated with 10 μM 4HNE and either vehicle or 1 μM midi-GAGR for 24 h prior to cell viability/cytotoxicity assay. As controls, neurons were treated with SU5402, midi-GAGR, 4HNE, 4HNE plus midi-GAGR, or SU5402 plus midi-GAGR.

For cell viability/cytotoxicity measurement, neurons on glass coverslips were incubated in 1 x PBS containing 2 μM calcein AM (live cells: green) and 4 μM ethidium homodimer-1 (dead cells: red) for 10 min at 37°C. Immediately thereafter, neurons were imaged by 10 x objective using a fluorescence Olympus IX71 microscope (Olympus America Inc., Center Valley, PA) and, for the acquisition of high-quality images, using TCS SP5 multi-photon laser scanning confocal microscope.

Co-culturing of microglial cells and primary rat cortical neurons

Microglial cell culture was prepared from the whole brain tissues (except of the cerebellum) of rat pups at postnatal day 3 (P3). Briefly, whole brain tissues except of the cerebellum were dissected and re-suspended in L-15 media on ice. Brain tissues were centrifuged at 1,000 x g for 3 min at 4°C. After the supernatant over brain tissue pellet was removed, the pellet was re-suspended in fresh L-15 media, followed by mechanical digestion using pasteur pipette. After the digestion, the resuspension was filtered through cell strainer (pore diameter = 70 μm). The flow-through was centrifuged at 1,000 x g for 3 min at 4°C. Then, cell pellet was re-suspended in DMEM media containing 10% FBS and 1X penicillin/streptomycin and plated at a high density in T75 culture flasks. The medium was exchanged with fresh medium every four days. After 8–10 days, culture flask caps were covered with parafilm to prevent gas exchange with environmental air. Flasks were then shaken in an orbital shaker at 220 rpm for 4 h at 37°C. Media was then collected into a conical tube and centrifuged at 800 x g for 10 min. The resulting cell pellet (mostly microglial cells) was then re-suspended in a neurobasal media containing
B27 supplement and plated in filter insert (0.4-μm pore diameter) at a density of 2 x 10^5 cells. The filter inserts containing microglial cells were transferred to a 24 well plate containing rat cortical neuron cultures (DIV6) at the bottom of each well. Microglial cells were treated with either 2 μM Aβ42 peptide or vehicle (H2O) and neurons with either 1 μM midi-GAGR or vehicle (H2O) for 48 h prior to live-dead assay. In addition, we examined whether microglial cells penetrated the filter and fell down to neurons at the bottom of well or not by staining the cells on coverslips at the bottom of well by staining the coverslips with anti-Iba1 antibody for immunocytochemistry and confocal microscopy.

Analysis of neurite outgrowth and pCREB in primary mouse cortical neurons

To analyze the effect of polysaccharides on neurite outgrowth, primary mouse cortical neurons were treated with vehicle (H2O) or 1 μM of dextran, alginate, or midi-GAGR, 0.01 μM of HA-GAGR, or 0.1 μM of LA-GAGR for 2 days prior to immunocytochemistry using anti-α-tubulin antibody and secondary Alexa488nm antibody. An etched grid coverslip containing 200 numbered boxes was used to select neurons objectively for image acquisition and analysis. A total of 24 boxes were randomly selected per treatment group. All the neurons having total neurite length longer than 4 times of the diameter of neuron cell body were chosen for image analysis. The total length of the neurites of each neuron was measured using Metamorph and used to calculate average total neurite length. To examine the effect of polysaccharides on the phosphorylation (activation) of nuclear CREB, neurons were stained with anti-pCREB antibody (Abcam & Santa Cruz biotechnologies, 2nd antibody with Alexa568nm), anti-α-tubulin antibody (Sigma, 2nd antibody with Alexa488nm), and DAPI (Sigma) after two-day incubation with vehicle (H2O) or 1 μM of dextran, alginate, or midi-GAGR, 0.01 μM of HA-GAGR, or 0.1 μM of LA-GAGR. Then, to identify midi-GAGR-induced signaling pathway that induces CREB phosphorylation, primary mouse cortical neurons were pre-treated with the inhibitors of FGFR1 (SU5402 [Santa Cruz Biotechnologies], 4 μM), PKC (staurosporine [Sigma], 3 nM), MEK (U0126 [Sigma], 10 μM), PI3K (LY294002 [Sigma], 20 μM), CaMKII (KN-62 [Calbiochem, Billerica, MA], 10 μM), or FAK (PF-573228 [Sigma], 1 μM) for 6 h and then with 1 μM midi-GAGR for 48 h prior to the staining of pCREB and α-tubulin. The images of neurons on coverslips were taken by confocal microscopy at the same gain (850), offset (-0.01) and exposure time (2 sec). The intensity of the staining of nuclear pCREB was measured using Metamorph and used to calculate average intensity. In addition, we detected the phosphorylation of CREB in the cytosols of mouse cortical neurons treated with polysaccharides by immunoblotting. Primary mouse neurons were dissected from 16 mouse embryos (E17) and plated in the wells of 6-well plates (1 x 10^6 cells/well), differentiated for 6 days, and treated with polysaccharides for 48 h. Then, neurons were harvested and lysed in 1% Igepal CA-630 (Sigma)-containing PMEE buffer plus protease and phosphatase inhibitor cocktails (Sigma) for protein extraction. Extracted proteins were separated in 4–12% NuPAGE Bis-Tris protein gels (Life Technologies) and transferred to nitrocellulose membrane (GE Healthcare Life Science, Pittsburgh, PA) using a semidry blotter (Hoefer, Inc. San Francisco, CA). The protein bands on blots recognized by anti-pCREB (Santa Cruz Biotechnologies) and anti-CREB antibodies were detected on Amersham Hyperfilm™ ECL films (GE Healthcare Life Science) using SuperSignal® West Pico Chemiluminescent Substrate (Thermo Scientific).

Examination of the in vivo neurotrophic effect of midi-GAGR

40 μL of 1 mM midi-GAGR or sterile H2O (vehicle) was administered intranasally into the nostrils (20 μL/nostril) of SD rats (4 rats per each) using a pipette. Animals were kept in
a novel neurotrophic polysaccharide, midi-gagr

anesthetized condition using 4% isoflurane and at supine position during administration to prevent the squirting-out of drug. Animals were sacrificed by decapitation at 6 h, 24 h, or 48 h after the administration. Whole brain was micro-dissected into the frontal cortex, hippocampus, and the rest of brain. Then, tissues were homogenized in the 2-fold volume of 1 x PMEE buffer containing 1% Igepal CA-630 and protease inhibitor cocktail using a 2-mL Teflon homogenizer. The homogenization was then incubated on ice for 30 min at 4°C, followed by centrifugation at 14,500 x g for 30 min. The supernatant was collected and its protein concentration was measured by Bradford assay. 20 μg of proteins was loaded onto each well of NuPage 4–11% Bis-Tris protein gels. Immunoblotting was performed using the antibodies to NF200, GAP-43, and GAPDH. The densities of protein bands were measured using Image J and normalized to that of the loading control, GAPDH. Normalized values were used to calculate average normalized band densities.

examination of the interaction of midi-gagr with fgfr1 in brain synaptosomal plasma membrane

to examine whether midi-gagr interacts with synaptosomal fgfr1 or not, we performed affinity chromatography using midi-gagr-conjugated sepharose beads. We conjugated either midi-gagr or dextran to epoxy-activated sepharose 6b that is a pre-activated medium that can be conjugated to the hydroxyl groups of carbohydrates. Briefly, 200 μl of 7.4 mM midi-gagr or 5kD dextran in H2O was mixed with 200 μl of epoxy-activated sepharose beads in a microtube and incubated on a rotator (16 h, 37°C). The mixture was spun down at 1,000 x g (10 min) to separate bead-bound polysaccharides from unbound. Unoccupied active sites on beads were blocked by incubation (4 h, 45°C) in 1 M ethanolamine (pH 8). Then, beads were washed with three cycles of alternating pH solutions– 0.1 M acetate buffer (pH 4) and 0.1 M Tris-HCl buffer (pH 8), both containing 0.5 M NaCl. The conjugation of polysaccharides to beads was confirmed by phenol—sulfuric acid colorimetry [87]. Cerebral cortices were dissected from four female mice (BALB/C, 8 wks old) and homogenized with a hand grinder in 1 mL of PMEE homogenization buffer plus 1% Igepal CA-630 and protease inhibitors (PIs). The homogenate was centrifuged at 1,000 x g (10 min) to remove nuclei and undisrupted cells. The supernatant was subjected to 5–6 strokes through 27G needle. Post-nuclear supernatant was centrifuged at 1,000 x g (15 min). The supernatant was diluted to 1:2 with Igepal CA-630-free PMEE buffer (to make 0.5% Igepal CA-630) and stored at -80°C until use. Then, the supernatant was incubated with 100 μl of either midi-gagr-conjugated or dextran-conjugated beads. After 24-h incubation on a rotator at 4°C, the beads were washed three times with 0.5 mL of PMEE buffer to remove proteins that nonspecifically bind to beads. Then, the beads were boiled for protein elution in a SDS loading buffer. Eluted proteins were separated in a SDS-NuPAGE gel and processed for immunoblotting using FGFR1 antibody.

examination of the effects of midi-gagr on neuronal activity and neurodegenerative markers in 3xTg AD mice

We purchased 12-week-old 3xTg-AD mice (female, ~20 g, B6.Cg-Psen1tm1Mpm Tg [APPSwe, tauP301L]1Lfa/J) to examine the efficacy of midi-gagr in restoring neuronal activity and reducing neurodegeneration in AD mouse brains. Three 3xTg AD mice were intranasally administered with either sterile H2O (vehicle) or 1 mM midi-gagr (40 μL total, 20 μL/nostril) every day for 14 days after 4% isoflurane anesthetization and then sacrificed by decapitation. Whole brain was micro-dissected to obtain the cortices and hippocampi. The tissues were homogenized in the 2-fold volume of 1 x PMEE buffer containing 1% Igepal CA-630 plus phosphatase and protease inhibitor cocktail using a miniature cell grinder for 1.5 mL.
microtube. The homogenization was then incubated on a rotator for 30 min at 4°C, followed by centrifugation at 14,500 x g for 30 min. The supernatant was collected and its protein concentration was measured by Bradford assay. 30 μg of proteins was loaded onto NuPage 4–11% Bis-Tris protein gels. Immunoblotting was performed using the antibodies to NF200, GAP-43, PSD95, synaptophysin, pCREB, CREB, p-tau (AT8), tau, and GAPDH. The densities of protein bands were measured using Image J and normalized to that of the loading control, GAPDH. Normalized values were used to calculate average normalized band densities.

Statistical Analysis

All cell culture experiments were replicated multiple times with different batches of cell cultures. Microscopic analysis was performed blindly by students. Statistical significance between two groups was calculated using unpaired student’s t-test with a value of p<0.05 that was considered statistically significant. Multiple comparisons were performed using one-way ANOVA followed by Dunnett’s or Bonferroni’s multiple comparisons tests (GraphPad Prism software, La Jolla, CA).

Results

Generation of small-size polysaccharides from low acyl gellan gum

We had searched for a neuroprotective polysaccharide among those that are currently used in human as food additive. Then, we found the strong neuroprotective polysaccharide, low acyl gellan gum (LA-GAGR). 1 μM LA-GAGR protected differentiated N2A cells and their neurites from high doses of 4HNE (data not shown), a reactive lipid radical that causes neurodegeneration [88, 89]. In order to increase water solubility and diffuse-ability, we cleaved LA-GAGR into smaller sizes by enzymatic digestion (α(1→3)-glycosidase) for 24, 48, and 72 h. The MWs of its cleavage products were determined using Parallel Plate Rheometer that measures shear storage modulus and loss modulus and yields the viscosity profile of polysaccharides. From the viscosity-storage modulus profiles, the MW distributions of the cleavage products were determined using RheoAnalyzer program. The validity of the RheoAnalyzer program was verified by running polystyrene standard (NBS 706) on the Parallel Plate Rheometer and determining MW from the viscosity profile. The MW distributions of LA-GAGR and its 24-h, 48-h, and 72-h digestions are shown in ‘S1 and S2 Appendices’. The average MW of LA-GAGR was ~99,639 g/mole that is close to the value reported by CPKelco Co. The MWs of 24-h, 48-h, and 72-h cleavage products were ~30,245 g/mole, ~4,775 g/mole, and ~718 g/mole, respectively. The average MW of ~4,775 g/mole (named ‘midi-GAGR’) is equivalent to six repeating units and that of ~718 g/mole (named ‘mini-GAGR’) is to one repeating unit. Two small-size LA-GAGR products, midi-GAGR and mini-GAGR, were chosen for further examination regarding their neuroprotective effect.

Midi-GAGR rescues neurites from the atrophy caused by 4HNE and H2O2

We used differentiated N2A cells to examine if midi-GAGR and mini-GAGR protect neurites from the oxidative insults of 4HNE and H2O2 as LA-GAGR does. We, first, determined the atrophic dose ranges of the radicals by treating differentiated N2A cells with increasing concentrations of 4HNE and H2O2 for 48 h and 24 h, respectively. Treated cells were fixed, immunostained by anti-α-tubulin antibody, imaged by confocal microscopy, and examined regarding total neurite length. The average total neurite length of N2A cells was decreased in a dose-dependent manner in response to 4HNE and H2O2 to maximum extents at 25 μM
4HNE (Fig 2B and 2D) and 200 μM H₂O₂ (Fig 2C and 2E) compared to vehicle (Fig 2A). It suggests that 25 μM and 200 μM are the maximum doses of 4HNE and H₂O₂, respectively, that causes almost complete neurite atrophy in differentiated N2A cells. Then, we treated differentiated N2A cells with increasing concentrations of mini-GAGR prior to the treatment with either 25 μM 4HNE or 200 μM H₂O₂. Treatment with 0.1 and 1 μM midi-GAGR prior to 4HNE treatment rescued neurites up to ~70% of the control level (vehicle) (Fig 2F and 2H). Similarly, treatment with 0.1 and 1 μM midi-GAGR prior to H₂O₂ treatment rescued neurites up to ~100% of the control level (Fig 2G and 2I). We also examined the protective effect of mini-GAGR but found that mini-GAGR was not as potent as midi-GAGR in protecting neurites from the free radicals (data not shown). Therefore, we chose midi-GAGR that showed stronger neuroprotective effect against 4HNE and H₂O₂ for further study.

**Midi-GAGR reduces the apoptosis of rodent cortical neurons caused by 4HNE, H₂O₂, and amyloid β peptide**

Based on our observation that midi-GAGR attenuated neurite atrophy caused by free reactive radicals, we speculated that mini-GAGR might protect neurons from the death caused by free radical insults. Thus, we examined the extent to which midi-GAGR protects the primary culture of rodent cortical neurons from 4HNE and H₂O₂. In addition to the radicals, we tested amyloid β peptide (Aβ₄₂) because Aβ₄₂ peptide is a major causative factor that causes oxidative stress and neuron death [90, 91]. We treated mouse cortical neurons (E17, DIV5) with 10 μM 4HNE (24 h), 50 μM H₂O₂ (24 h), or 2 μM Aβ₄₂ peptide (48 h) after the treatment of the neurons with vehicle (H₂O), midi-GAGR (1 μM), dextran (1 μM), alginate (1 μM), LA-GAGR (0.1 μM), or HA-GAGR (0.01 μM) for 24 h. The concentrations of 4HNE, H₂O₂, and Aβ₄₂ peptide were chosen according to their patho-physiological concentrations [89, 92–95]. The concentrations of LA-GAGR and HA-GAGR were chosen because, within the same volume, the total numbers of sugar units in the polysaccharides at the concentrations are close to that of 1 μM midi-GAGR. The viability of neurons was assessed using LIVE/DEAD® Viability/Cytotoxicity Assay Kit in which membrane-permeant calcein AM is cleaved by esterase in live cells, thus yielding green fluorescence, and membrane-impermeant ethidium homodimer-1 stains the nucleic acids of plasma membrane-compromised cells with red fluorescence. We counted the numbers of green (live) and red (dead) neurons in each condition using Metamorph. Although the intensities of green fluorescent signals in neurons treated with either free radicals or Aβ₄₂ peptide were weak, we included the neurons in our counting. About 8–9% of vehicle-treated neurons died during the process of live/dead cell assay (Figs 3A and 4). Upon exposure to 10 μM 4HNE, ~26% of mouse cortical neurons died (Figs 3B and 4A) while pre-treatment with 1 μM mini-GAGR (Fig 3C) and 0.1 μM LA-GAGR reduced neuron death to 14% and 10%, respectively (Fig 4A). HA-GAGR and alginate also reduced the percent of neuron death caused by 4HNE while dextran did not (Fig 4A). Exposure to 50 μM H₂O₂ caused neuron death in ~25% of cortical neurons that were pre-treated with vehicle (Figs 3D and 4B). Pre-treatment with either alginate or dextran did not reduce H₂O₂-caused neuron death (Fig 4B). Conversely, pre-treatment with mini-GAGR (Fig 3E), LA-GAGR, or HA-GAGR reduced neuronal death to ~13% (Fig 4B). These results suggest that mini-GAGR, LA-GAGR, and HA-GAGR can protect rodent cortical neurons from both H₂O₂ and 4HNE while dextran and alginate cannot.

We, then, examined the extent to which midi-GAGR protects cortical neurons from Aβ₄₂ peptide. Exposure to 2 μM Aβ₄₂ peptide caused the death of about 30% of neurons pre-treated with vehicle (Figs 3F and 4C). Pre-treatment with HA-GAGR, alginate, or dextran did not decrease the percent of neuron death compared to pre-treatment with vehicle (Fig 4C).
Fig 2. Midi-GAGR reverses neurite atrophy caused by 4HNE and H2O2. (A-E) Differentiated N2A cells were treated with different concentrations of 4HNE (0, 1, 5, 10 and 25 μM) for 48 h or H2O2 (0, 1, 10, 50, 100 and 200 μM) for 24 h and immunostained with α-tubulin antibody. The representative images of N2A cells treated with H2O (vehicle) (A), 25 μM 4HNE (B), or 200 μM H2O2 (C). Scale bar = 75 μm. Bar graphs represent the average total neurite lengths of N2A cells in response to different concentrations of either 4HNE (D) or H2O2 (E). *, p < 0.05 and **, p < 0.001 compared to control. (F-I) Differentiated N2A cells were pre-treated with different concentrations (0, 0.001, 0.01, 0.1, 1, and 10 μM) of midi-GAGR for 24 h, followed by incubation with either 25 μM 4HNE for 48
Conversely, pre-treatment with either midi-GAGR or LA-GAGR reduced neuron death to ~10%, the control level (Figs 3G and 4C). Thus, only midi-GAGR and LA-GAGR can protect cortical neurons from Ab42 peptide while other polysaccharides cannot.

**Midi-GAGR reduces the apoptosis of rodent cortical neurons from co-treated 4HNE or Aβ42 peptide**

It is likely that free reactive radicals already exist at pathological concentrations inside the brain before some symptoms are noticeable for treatment. In other words, treatment is likely to start at the pre-existence of the pathological concentrations of the radicals. Thus, we examined if midi-GAGR can protect cortical neurons from co-treated 4HNE or Aβ42 peptide. Rat cortical neurons (E17, DIV5) were treated with either 10 μM 4HNE (24 h) or 2 μM Aβ42 peptide (48 h) and either vehicle or 1 μM midi-GAGR. Then, the viability of neurons was assessed using LIVE/DEAD Viability/Cytotoxicity Assay Kit. Exposure to 10 μM 4HNE caused apoptosis in ~27% of vehicle-treated neurons while co-treatment with midi-GAGR reduced the percent of neuron death to ~9% (Fig 5A). Treatment with 2 μM Aβ42 peptide caused death in ~29% of vehicle-treated neurons while co-treatment with midi-GAGR reduced the percent of neuron death to ~15% (Fig 5A). These results suggest that midi-GAGR can also protect rodent cortical neurons from co-treated 4HNE or Aβ42 peptide.

**Midi-GAGR protects rodent cortical neurons from microglial cells activated by Aβ42 peptide**

Microglial cells activated by Aβ42 peptide are a major causative factor for neurodegeneration, especially AD [96]. As such, activated microglial cells secrete free radicals and pro-inflammatory cytokines that facilitate neurodegeneration and neuron apoptosis. Thus, we examined if midi-GAGR protects primary rodent cortical neurons from microglial cells activated by Aβ42 peptide. Microglial cells were isolated from rats on the postnatal day 1 (S3 Appendix) and seeded in 0.4μm-pore-size filter insert that fits into the well of 24-well plate. The filter inserts were transferred to a 24-well plate in which primary rat cortical neurons (E17) were cultured at the bottoms of wells for 6 days (DIV6). Then, microglia cells were treated with 2 μM Aβ42 and neurons with either vehicle or 1 μM midi-GAGR. After 48 h, the viability of neurons was assessed using LIVE/DEAD Viability/Cytotoxicity Assay Kit. Around 25% of the neurons treated with vehicle died under untreated microglial cells (Fig 5B). Upon treatment of microglial cells with Aβ42 peptide, the percent of death in neurons treated with vehicle was increased to ~40%. Conversely, treatment of neurons with 1 μM midi-GAGR reduced death to ~27% that was close to the percent of dead neurons under untreated microglial cells (Fig 5B). Thus, it is clear that midi-GAGR can protect rodent cortical neurons from activated microglial cells.

**Midi-GAGR enhances neurite outgrowth in N2A cells and rodent cortical neurons**

In addition to the neuroprotective effect, we found that LA-GAGR enhanced neurite outgrowth in N2A cells. Thus, we expected that midi-GAGR would have a similar enhancing effect.
Fig 3. Pre-treatment with midi-GAGR significantly reduces the apoptosis of rodent cortical neurons caused by 4HNE, H$_2$O$_2$, and amyloid β peptide. (A-G) Mouse cortical neurons at DIV5 were pre-treated with H$_2$O (vehicle), 1 μM midi-GAGR, 0.1 μM LA-GAGR, 0.01 μM HA-GAGR, 1 μM alginate or 1 μM dextran.
on neuritogenesis. First, we examined the neuritogenic effect of midi-GAGR on N2A cells. N2A cells were differentiated with increasing concentrations (0, 0.001, 0.01, 0.1, 1, and 10 μM) of midi-GAGR for 48 h. Then, cells were fixed and immunostained with anti-α-tubulin antibody. The total length of neurites per cell was measured using Metamorph and used to calculate average total neurite length per treatment group. At 0.1 and 1 μM, the average total neurite length of midi-GAGR-treated N2A cells reached ~1.7 fold higher than that of vehicle-treated cells (Fig 6; 438.21±20.55 μm [0.1 μM] and 457.76±41.66 μm [1 μM] vs. 257.51±45.16 μm [vehicle], p < 0.05). At 10 μM, average total neurite length was decreased, which is similar to the pattern of neuritogenesis in cells treated with FGL [79]. We also examined the neuritogenic effect of midi-GAGR on primary mouse cortical neurons (E17, DIV4). Neurons were incubated with vehicle, midi-GAGR (1 μM), dextran (1 μM), alginate (1 μM), LA-GAGR (0.1 μM), or HA-GAGR (0.01 μM) for 2 days and immunostained with the antibody to βIII tubulin (Fig 7A–7F). The total neurite length of each neuron was measured to calculate average total neurite length per condition. Then, average total neurite length per condition was divided by that of vehicle treatment to obtain fold change in average total neurite length per condition. Compared to vehicle treatment (Fig 7A), midi-GAGR (Fig 7B) and LA-GAGR (Fig 7C) increased average total neurite length by ~1.6 fold (Fig 7G). Conversely, HA-GAGR (Fig 7D), alginate (Fig 7E), and dextran (Fig 7F) did not enhance neuritogenesis (Fig 7G). Thus, only midi-GAGR and LA-GAGR have strong neuritogenic effect on rodent cortical neurons.

**Mid-GAGR activates CREB, a neurotrophic transcriptional factor**

Since both survival-enhancement and neuritogenesis converge on neurotrophic effect [33, 97], it is possible that midi-GAGR activates a neurotrophic signaling pathway that increases neuron survival in neurodegenerative condition and enhances neuritogenesis. To examine the possibility, we stained midi-GAGR-treated mouse cortical neurons with the antibody to pCREB, a marker for activated neurotrophic signaling pathways [98–100]. Mouse cortical neurons (E17, DIV4) were treated with vehicle (Fig 8A), midi-GAGR (1 μM, Fig 8B), alginate (1 μM, Fig 8C), dextran (1 μM, Fig 8D), LA-GAGR (0.1 μM), or HA-GAGR (0.01 μM) for 48 h, fixed, immunostained with the antibodies to α-tubulin and pCREB along with DAPI. The fluorescence intensity (arbitrary number) of stained pCREB in the nucleus was measured using Metamorph. Vehicle-treated neurons showed the basal levels of pCREB in the nuclei (Fig 8A). Conversely, treatment with either midi-GAGR (Fig 8B) or LA-GAGR significantly increased the level of nuclear pCREB while the other polysaccharides did not (Fig 8C and 8D). Treatment with HA-GAGR slightly increased the level of nuclear pCREB. We calculated the average intensity of stained pCREB in the nuclei of the neurons. Treatment with either midi-GAGR or LA-GAGR increased the average intensity of nuclear pCREB by ~2 fold compared to vehicle treatment (Fig 8E). To confirm the result of the optical measurement of the level of pCREB, we performed immunoblotting to detect the phosphorylation of CREB protein using the cytosols extracted from mouse cortical neurons treated with vehicle or polysaccharides. Total CREB was also detected by immunoblotting. Compared to control (vehicle treatment), the levels of pCREB were significantly increased in neurons treated with either midi-GAGR or LA-GAGR while those in neurons with either alginate or dextran were not (Fig 8F). The phosphorylation
Fig 4. Quantification of neuron death in response to oxidative insults in the presence of different polysaccharides. The numbers of live and dead cells were counted using Metamorph software. Bar graphs represent the percents of dead neurons after the pre-treatments with different polysaccharides followed by treatment with 4HNE (A), H$_2$O$_2$ (B), or A$eta_{42}$ (C). Data represent mean ± SEM of three independent experiments. For each experiment, at least, 1,000 cells per group were counted. *, p<0.05.

doi:10.1371/journal.pone.0149715.g004
Fig 5. Midi-GAGR protects rodent cortical neurons from co-treated 4HNE, Aβ42 peptide and activated microglial cells. (A) Rat cortical neurons (E17) at DIV5 were co-treated with either 10 μM 4HNE (for 24 h) or 2 μM Aβ42 (for 48 h) and either water or 1 μM midi-GAGR. After the treatment, neurons were processed for
live/dead assay using calcein AM and ethidium homodimer-I. Live and dead cells were imaged using a fluorescence microscope. The numbers of live and dead cells were counted using Metamorph software. Bar graphs show the percent of dead neurons after co-treatment with either 4HNE or Aβ42 plus/minus midi-GAGR. Data represent mean ± SEM of three independent experiments. *, p<0.05.

Intranasally administered midi-GAGR penetrates the BBB and increases the expression of NF200 and GAP-43 in the frontal cortex and hippocampus

Our previous study demonstrated that midi-GAGR penetrated the BBB and remained at 0.1–0.2 μM inside the brain for ~24 h after one-time intranasal administration [101]. Therefore, intranasally administered midi-GAGR is expected to exert a neurotrophic effect inside the brain within 24 h post-administration. We examined the expression of two neurotrophic protein markers, NF200 and GAP-43, in the brains of rats administered intranasally with 40 μL of either H2O or 1 mM midi-GAGR. At 6, 24, and 48 h after the intranasal administration, the frontal cortex, hippocampus, and the rest of the brain were dissected from the rats and processed for immunoblotting using the antibodies to NF200, GAP-43, and GAPDH (loading control). The protein band densities of NF200 and GAP-43 were measured by densitometry (Image J), normalized by those of GAPDH, and used to calculate average normalized values. In the frontal cortex, the expression level of NF200 was increased to the level significantly higher than control at 6 h and 24 h after the administration (Fig 9A and 9B). In the hippocampus, the expression level of NF200 was increased to the level statistically higher than control after 24 h. The expression level of GAP-43 was also significantly increased in the frontal cortex at 6 h and 24 h while slightly increased in the hippocampus at 24 h (Fig 9A and 9C). The rest of the brain did not show an increase in NF200 and GAP-43 after one-time intranasal administration. These results indicate that intranasally administered midi-GAGR enters the brain and exerts its neurotrophic effect in the frontal cortex and hippocampus within 24 h post-administration.

Midi-GAGR binds to FGFR1 and activates FGFR1 signaling pathway

Our pilot proteomics study hinted that midi-GAGR might interact with FGFR1 (data not shown). Thus, we examined the possible interaction of midi-GAGR with FGFR1 by affinity chromatography using midi-GAGR-conjugated sepharose column. Either midi-GAGR or dextran was conjugated to epoxy sepharose beads according to manufacturer’s protocol. Whole mouse brains were homogenized for cytosol extraction in PMEE buffer containing 1% Igepal CA-630 and protease inhibitor cocktail. Brain cytosols were diluted to 1:2 to make 0.5% Igepal buffer prior to the incubation with either dextran- or midi-GAGR-conjugated sepharose beads on a rotating plate for 16 h at 4°C. Nonspecific bindings were removed by extensive washes in PMEE buffer. Beads were boiled for protein elution. FGFR1 was one of the proteins eluted from midi-GAGR beads but not from dextran beads (Fig 10A). As midi-GAGR binds to FGFR1, midi-GAGR is expected to activate FGFR1 signaling pathway, which results in CREB phosphorylation. We used pharmacological agents to inhibit signaling molecules downstream of FGFR1 that mediate CREB phosphorylation. We measured...
the fluorescence intensities of nuclear pCREB in mouse cortical neurons (E17, DIV6) pre-treated for 6 h with the inhibitors of FGFR1 (SU5402 [SU], 4 μM), PKC (staurosporine [Stau], 3 nM), MEK (U0126 [U01], 10 μM), PI3K (LY294002 [LY], 20 μM), or CaMKII (KN-62 [KN], 10 μM) and then with 1 μM midi-GAGR (midi) for 48 h. PF-573228 (PF, 1 μM) that inhibits
Fig 7. Midi-GAGR enhances neuritogenesis in mouse cortical neurons. (A-F) Mouse cortical neurons (E17, DIV4) were treated with H₂O (vehicle) (A), 1 μM midi-GAGR (B), 0.1 μM LA-GAGR (C), 0.01 μM HA-GAGR (D), 1 μM alginate (C), or 1 μM dextran (F) for 48 h and immunostained with anti-α-tubulin antibody. Scale bar = 100 μm. (G) Bar graphs show average fold changes in the total neurite length of mouse cortical neurons in response to different polysaccharides (mean ± SEM of, at least, three independent experiments). **, p<0.01 compared to control.

doi:10.1371/journal.pone.0149715.g007
Fig 8. Midi-GAGR activates CREB, a neurotrophic transcriptional factor. Mouse cortical neurons (DIV4) were treated with H2O (vehicle), 1 μM midi-GAGR, 0.1 μM LA-GAGR, 0.01 μM HA GAGR, 1 μM alginate, or 1 μM dextran for 48 h and immunostained with DAPI (not shown) and the antibodies to α-tubulin and pCREB.
FAK which sits at the bottleneck of the signaling pathway downstream of NCAM180 [73] was also included to examine whether NCAM180 is involved in midi-GAGR-mediated CREB phosphorylation or not. Treated neurons were stained with the antibodies to βIII tubulin (red) and pCREB (green) for the measurement of the average intensities of nuclear pCREB. Compared to neurons treated with vehicle (Fig 10B and 10J), those with midi-GAGR (midi) showed a significant increase (~2.6 fold) in the average intensity of pCREB (Fig 10C and 10J). Conversely, pre-treatment with the inhibitor of FGFR1 (Fig 10D and 10J), PKC (Fig 10E and 10J), or MEK (Fig 10F and 10J) significantly decreased the average intensity of pCREB (solid lines, *: p<0.01, n = 40-50 neurons). In neurons pre-treated with the inhibitor of either PI3K or CaMKII, the average intensity of pCREB was decreased slightly but still statistically significantly (dotted lines, #: p<0.05, n = 40-50 neurons). In contrast to the inhibitors, pre-treatment with FAK inhibitor did not decrease the average intensity of pCREB in midi-GAGR-treated neurons (Fig 10I and 10J). These results suggest that midi-GAGR activates FGFR1 and its downstream signaling pathways consisting of PKC, MEK, PI3K, and CaMKII, but not NCAM180-FAK signaling pathway for CREB phosphorylation.

Next, we examined how much FGFR1-mediated neurotrophic signaling pathway contributes to midi-GAGR-mediated neuroprotection against oxidative insult. We pre-treated rat cortical neurons (E17, DIV6) for 6 h with FGFR1 inhibitor (SU5402, 4 μM) and then with 10 μM 4HNE for 24 h prior to LIVE/DEAD Viability/Cytotoxicity Assay. Treatment with 4HNE increased the percent of dead cells from ~20% to ~60% while co-treatment with 1 μM midi-GAGR decreased that to ~30% (Fig 10K). Treatment with SU5402 alone or SU5402 plus midi-GAGR did not increase the percent of dead cells (Fig 10K). Interestingly, pre-treatment with SU5402 significantly increased the percent of dead cells up to ~80% upon the post-treatment with 4HNE (Fig 10K). In neurons pre-treated with SU5402 and then treated with 4HNE, midi-GAGR could not decrease the percent of dead cells. This result indicates that FGFR1-mediated signaling pathway plays a major role in midi-GAGR-mediated neuroprotection against oxidative insult.

Intranasally administered midi-GAGR increases neuronal activity markers and reduces hyperphosphorylated tau in 3xTg-AD mice

Given that the activation of FGFR1 enhances neuronal activity and, possibly, attenuates neurodegeneration [51–53], we speculate that midi-GAGR treatment does the similar. Thus, we examined if midi-GAGR treatment increases the protein markers of neuronal activity and reduces the neurodegeneration marker, hyperphosphorylated tau (P-Ser202), in AD brain [102]. We used 12-month-old 3xTg-AD mice that harbor two familial AD mutations, APPswe and PS1M146V, and the tauP301L mutation found in frontotemporal dementia [103, 104]. Until 12 months of age, 3xTg-AD mice [103] develop synapse loss, Aβ peptide accumulation [105, 106], memory deficit [107], and tau hyperphosphorylation [103]. We used female 3xTg-AD mice since females show more obvious cognitive defects than males [108–110]. We administered 40 μL of vehicle (sterile H2O) or 1 mM midi-GAGR intranasally into female 3xTg-AD mice once per day for 14 days. During midi-GAGR administration, 3xTg-AD mice did not show any abnormal behavior. Of note, 3xTg-AD mice administered with midi-GAGR made
Fig 9. Intranasally administered midi-GAGR increases the expression of NF200 and GAP-43 in the brains of live rats. SD rats were intranasally administered with either vehicle or midi-GAGR and processed to obtain brains at 6h, 24h or 48h after the administration. Brains were dissected to the frontal cortex, hippocampus, and rest of the brain. (A) Brain tissue lysates were processed for immunoblotting using the antibody to NF200 (upper panel), GAP-43
tight nest every day while those with vehicle made loose nest as previously reported [111]. After 14-day administration, mice were killed for brain extraction. Extracted brains were dissected to obtain the cortices and hippocampi. The brain tissues were lysed in PMEE buffer containing 1% Igepal CA-630 and phosphatase and protease inhibitor cocktails for immunoblotting using antibodies to NF200, GAP-43, PSD95, synaptophysin (SYN), pCREB, CREB, p-tau (AT8), tau, and GAPDH. The protein band densities of detected proteins were normalized by those of GAPDH and used to calculate average normalized band density for each protein. Compared to 3xTg-AD mice administered with vehicle (Veh.), NF200 was increased significantly in the hippocampus of those with midi-GAGR while not changed in the cortex (Fig 11A and 11B). GAP-43 and PSD95, the postsynaptic markers for increased synaptic activity, were increased significantly in both cortex and hippocampus of 3xTg-AD mice treated with midi-GAGR compared to control while synaptophysin (SYN) remained unchanged (Fig 11A, 11C, 11D and 11E). pCREB, another postsynaptic marker that shows increased neurotrophic signaling, was also significantly increased in both cortices and hippocampi of 3xTg-AD mice treated with midi-GAGR compared to control (Fig 11A and 11F). Total CREB was slightly increased in the hippocampus of midi-GAGR-treated 3xTg-AD mice while not changed in the cortex (Fig 11A and 11G). Surprisingly, hyperphosphorylated tau (P-Ser202) was drastically decreased in the hippocampus of 3xTg-AD mice and slightly in their cortices (Fig 11A and 11H). Total tau was not changed (Fig 11A and 11I). These results indicate that intranasally administered midi-GAGR not only enhances neuronal and synaptic activities in the cortex and hippocampus but also decreased hyperphosphorylated tau, a major AD facilitator, in the brains of 3xTg-AD mice.

Discussion

Neurotrophic treatments have shown a promise in slowing neurodegeneration [8, 13–21, 23] while their in vivo pre-clinical and clinical trials do not yield satisfactory outcomes yet. The poor outcomes are mainly due to the poor BBB-permeability and short plasma half-life of neurotrophic peptides [32, 33]. Later, cell graft, Trojan horse, and nanoparticle were developed for the delivery of neurotrophic peptides [34–39] but still limited by several problems such as the unregulated expression of neurotrophic peptide, the complication accompanied with multiple surgeries, and still the short plasma half-life of neurotrophic peptide. As such, no solution has been found to overcome the limits of neurotrophic peptides.

Prompted by the findings of neuroprotective polysaccharides [40–43], we searched for an alternative to neurotrophic peptide and finally discovered a 4.7kD neurotrophic polysaccharide that appears to overcome the limitations of neurotrophic peptides. In consistent with our previous study [101], intranasally administered midi-GAGR penetrates the BBB and exerts its neurotrophic effect for 24 h after one time administration. It suggests that midi-GAGR has a good BBB-permeability and a long plasma half-life of ~24 h. The latter long plasma half-life of midi-GAGR was expected as other polysaccharides show long plasma half-life as well [44–47]. Likewise, the good BBB-permeability of intranasally administered midi-GAGR is not surprising as the amino polysaccharide, chitosan, shows high BBB-permeability through intranasal administration [37–39, 48, 49]. Although intranasal administration has shown mediocre efficacy in delivering peptides through the BBB, non-peptide agents have shown success in their penetration into human brains via intranasal administration [112–115].
Fig 10. Midi-GAGR binds to FGFR1 and uses FGFR1 signaling pathway to activate CREB and protect neurons from the death caused by oxidative insult. (A) Midi-GAGR- or dextran-conjugated epoxy sepharose beads were mixed with synaptosomal plasma membrane proteins in 0.5% Igepal CA-630 PMEE buffer to pull down midi-GAGR-interacting FGFR1. Precipitated FGFR1 was detected by immunoblotting (n = 2, four rat brains). (B-J) Mouse cortical neurons (DIV4) were pre-treated with H2O (vehicle, B,C) or the inhibitors of FGFR1 (SU5402 [SU], 4 μM, D), PKC (staurosporine [Stau], 3 nM, E), MEK (U0126 [U01], 10 μM, F), PI3K (LY294002 [LY], 20 μM, G), CaMKII (KN-62 [KN], 10 μM, H), or PF-573228 (PF, 1 μM, I) for 6 h and then with mock (B) or 1 μM midi-GAGR (+midi, C-I) for 48 h. Neurons were then immunostained with the antibodies to α-tubulin (red) and p-CREB (green). Scale bar = 100 μm. (J) Bar graphs show the average intensities of pCREB after different treatments (n = 60 neurons, mean ± SEM). * p<0.01 and # p<0.05 compared to control. (K) Rat cortical neurons (E17, DIV6) were treated for 6 h with FGFR1 inhibitor (SU5402, 4 μM) and treated with 10 μM 4HNE and either vehicle or 1 μM midi-GAGR for 24 h prior to cell viability/
Given that midi-GAGR is derived from the human food additive, low acyl gellan gum (LA-GAGR), that has few side effects in human [50] and animals (FDA report), we speculate that midi-GAGR would not have serious side effect in human if clinically applied in the future. As such, ingested low acyl gellan gum that is expected to be digested to the size similar to that of midi-GAGR by natural cleavage does not show any side effects. Indeed, during our study, animals administered daily with midi-GAGR for two weeks did not show any abnormality in general behaviors such as moving, eating, sleeping, skin sensitivity, grouping, etc. Nevertheless, a possible toxicity of midi-GAGR should be examined in our next study. Meanwhile, one noticeable thing was that midi-GAGR-treated 3xTg-AD mice showed better nesting behavior than vehicle-treated. The nesting behavior is known to be impaired in 3xTg-AD mice, which corresponds to "deterioration of executive functions and daily live activities (DLA)" in human [111]. DLA is used along with the behavioral and psychological symptoms of dementia to diagnose early AD in human. Moreover, nesting behavior heavily depends on the hippocampus [116]. We believe that midi-GAGR may rescue some hippocampal function involved in nesting behavior. The nesting behavior of 3xTg-AD mice treated with midi-GAGR will be examined in our further study.

In our in vitro experiments, midi-GAGR showed a strong neuroprotective effect. At 0.1–1 μM, midi-GAGR protected the neurites of differentiated N2A cells up to 70–90% from the atrophy caused by the supra-physiological concentrations of two free reactive radicals, 4HNE and H2O2. At 1 μM, midi-GAGR protected primary rodent cortical neurons from the pathological concentrations of post-/co-treated free radicals and amyloid β42 peptide. The protective effect of midi-GAGR against co-existing free radicals and amyloid β42 peptide is clinically relevant as treatment is usually applied to the pre-existing pathological conditions like high levels of free radicals and amyloid β42 peptide. We also observed that 1 mM midi-GAGR protected rodent cortical neurons from more vicious neurodegenerative factor, activated microglial cells [96]. Thus, it is clear that midi-GAGR is a strong neuroprotective agent. In contrast, the control polysaccharides, dextran (D-Glc polymer), alginate (D-GlcA polymer), and HA-GAGR (highly acylated LA-GAGR), could not protect neurons from both free radicals and amyloid β42 peptide. Thus, the neuroprotective effect of midi-GAGR appears to be sequence-specific, which may confer midi-GAGR a specific binding to a certain molecule such as receptor.

In addition to the neuroprotective effect, midi-GAGR showed a strong neurotrophic effect both in vitro and in vivo. In vitro, midi-GAGR greatly enhanced neuritogenesis in N2A cells at 0.1–1 μM and in rodent cortical neurons at 1 μM. Other control polysaccharides such as dextran, alginate, and HA-GAGR could not enhance neuritogenesis. Similarly, in rodent cortical neurons, midi-GAGR increased the nuclear levels of activated pCREB, the transcriptional factor that enhances neuronal activities for survival and memory [117–119], while dextran and alginate did not. HA-GAGR appears to activate CREB to some extent but less than midi-GAGR. We observed a similar neurotrophic effect of midi-GAGR in the brains of rodents that were intranasally administered with midi-GAGR. In the frontal cortices and hippocampi of midi-GAGR-administered animals, the markers for neuritogenesis (NF200) and synaptic activity (GAP-43) were increased within 24 h after one-time intranasal spray. Thus, these in vitro and in vivo evidences clearly manifest the neurotrophic property of midi-GAGR.
Fig 11. Intranasally administered midi-GAGR increased neuronal activity markers and decreased hyperphosphorylated tau in 3xTg-AD mice. (A) 12-week-old 3xTg-AD mice were intranasally administered with 40 μL (20 μL/nostril) of either sterile H2O (Veh.) or 1 mM midi-GAGR (midi) every day for 14 days and processed to obtain the cortex and hippocampus (Hippo). The tissues were homogenized to extract proteins for immunoblotting using the antibodies to NF200, GAP-43, PSD95, synaptophysin, pCREB, CREB, p-tau (AT8), tau, and GAPDH. (B-J) The densities of protein bands were measured using Image J and normalized to that of the loading control, GAPDH. Normalized values were used to calculate the average normalized band densities of NF200 (B), GAP-43 (C), PSD95 (D), synaptophysin (E), pCREB (F), total CREB (G), p-tau (H), and total tau (I). Data represent mean ± SEM of three independent animals. #, p < 0.01, *, p < 0.05.
Our next question was what is the neurotrophic mechanism used by midi-GAGR? To find an answer, we performed pulldown experiment and pharmacological inhibitor study and found that midi-GAGR interacts with FGFR1 and appears to activate two FGFR1 signaling pathways, FRS2a-Shc-Grb2-PKC-Raf-MEK and PI3K-Akt/PLCγ-Ca2+-CaMKII pathway [73, 75, 76]. Based on the observation that the levels of pCREB were reduced more drastically by PKC and MEK inhibitors than by PI3K and CaMKII, FRS2a-Shc-Grb2-PKC-Raf-MEK pathway plays a more major role than PI3K-Akt/PLCγ-Ca2+-CaMKII pathway for CREB activation. We also found that FAK is not involved in midi-GAGR-FGFR1 signaling pathway as midi-GAGR-induced CREB phosphorylation was not decreased by the inhibitor of FAK that sits at the bottleneck of NCAM180 signaling pathway [73]. In our opinion, the selective activation of FGFR1 over NCAM180 (possibly, other NCAMs, too) should be beneficial in the clinical application of midi-GAGR since the activation of NCAM often leads to undesired effects [120]. Meanwhile, it is unclear yet whether midi-GAGR binds to FGFR1 in the similar manner to either FGF or FGL. Nonetheless, both FGF (e.g., FGF2) and FGL have shown a great efficacy in attenuating neurodegeneration and improve memory in AD mice (FGF2 [60–68]; FGL [52, 79–83]). Moreover, both FGF2 and FGL reduce AD pathogenic factors (FGF2 [69, 70]; FGL [82]). Therefore, midi-GAGR may exert the similar beneficial effects to FGF or FGL while with longer plasma half-life than those peptides.

As most polysaccharides are good antioxidants, midi-GAGR and other control polysaccharides used in our study were expected to show some extents of protection of cells and neurons from free reactive radicals. However, at the low concentrations below 1 μM, dextran and alginate could not protect rodent cortical neurons from the pathological concentrations of 4HNE and H2O2. Moreover, the polysaccharides and HA-GAGR could not protect the neurons from the relatively low but pathological concentration (2 μM) of Aβ42 peptide. In contrast to the control polysaccharides, midi-GAGR as well as LA-GAGR could protect the neurons from all three neurodegenerative factors, 4HNE, H2O2, and Aβ42 peptide. This result indicates that the neuroprotective effect of midi-GAGR does not depend on its antioxidant property. To further clarify this, we pre-treated rodent cortical neurons with FGFR1 inhibitor prior to the treatment with 4HNE. Midi-GAGR could not rescue neurons from 4HNE-induced death in neurons pre-treated with FGFR1 inhibitor, suggesting that FGFR1-mediated neurotrophic signaling pathway is the major mechanism by which midi-GAGR rescues neurons from oxidative insult-induced death. What is more, FGFR1 inhibitor increased the percent of neuron death caused by 4HNE to even higher than vehicle plus 4HNE. This suggests that FGFR1 is essential for neuron survival in the presence of high oxidative insult.

As discussed thus far, midi-GAGR has a great therapeutic potential (neurotrophic, neuroprotective, BBB-permeable, and long plasma half-life) for the treatment of neurodegenerative diseases, especially AD. Thus, we examined briefly the efficacy of midi-GAGR in enhancing neuronal activity and reducing pathogenic factor in the brains of 3xTg-AD mice that are known to demonstrate most AD pathogenic progresses until the age of 12 month [121]. In consistent with the results of SD rats, intranasally administered midi-GAAR increased both NF200 and GAP-43, the markers of increased neuritogenesis and synaptic activity, respectively, in the hippocampus. In the cortex, only GAP-43 was increased while NF200 was not changed. No change in NF200 in the cortex may be due to the saturation of the neuritogenic effect of midi-GAGR at the concentration of equal to or higher than 1 μM similarly to the result of our in vitro experiment (Fig 6). In addition to NF200 and GAP-43, PSD95 and pCREB, the indicators of increased synaptic activity, were also increased in both cortex and hippocampus. The increase in all four markers for enhanced neuronal activity in the brain of 3xTg-AD mice is the undoubtful evidence that shows a great potential of midi-GAGR for restoring the learning and memory function of the brain in AD mice.
In addition to the increases in neuronal activity markers, we were surprised to observe the reduction of hyperphosphorylated tau (P-Ser202) in the hippocampi of 3xTg-AD mice. Hyperphosphorylated tau is a reliable biomarker for “mild cognitive impairment” (MCI) \[122, 123\] at early AD. Hyperphosphorylation impairs the function of tau in promoting microtubule polymerization, resulting in its aggregation to form neurofibrillary tangles (NFTs), microtubule disassembly, and loss of axonal microtubule-based transport \[102, 124\]. Given that the mechanism by which the hyperphosphorylation of tau is regulated is complicated \[125–130\], another intensive study is needed to address how midi-GAGR decreases tau hyperphosphorylation. Nonetheless, we speculate that midi-GAGR may inhibit GSK3β, the major kinase responsible for tau hyperphosphorylation, in a similar way to FGL \[82\].

**Conclusions**

We discovered a BBB-permeable, long plasma half-life, strong neuroprotective and neurotrophic polysaccharide, midi-GAGR. Midi-GAGR is a small cleavage product of low acyl gellan gum that is an FDA-approved food additive that has few side effects in human. BBB-permeable midi-GAGR can exert its neurotrophic effect in the cortex and hippocampus for ~24 h after one-time intranasal administration. Moreover, midi-GAGR not only increases protein markers for increased neuronal activity but also reduces hyperphosphorylated tau in the brains of 3xTg-AD mice. To this end, we believe that all the great properties of midi-GAGR show its great potential as therapeutic agent for the treatment of neurodegenerative diseases especially AD. If clinically developed, midi-GAGR is expected to improve the neurotrophic treatment of neurodegenerative diseases.

**Supporting Information**

**S1 Appendix.** 24-h enzymatic digestion of low acyl gellan gum (LA-GAGR). The viscosity—storage modulus profiles showing the MWs of LA-GAGR (A) and its cleavage product after 24-h enzymatic hydrolysis (B).

(EPS)

**S2 Appendix.** 48-h and 72-h enzymatic digestion of LA-GAGR. The viscosity—storage modulus profiles showing the MWs of the cleavage products of LA-GAGR after 48-h (A) and 72-h (B) enzymatic hydrolysis.

(EPS)

**S3 Appendix.** Immunostaining of purified microglial cells with the antibody to Iba-1. Purified microglial cells were plated on glass coverslips coated with poly-L-lysine. After 24 h, microglial cells were fixed and immunostained with Iba-1 (microglial marker, green) and βIII-tubulin (neuron marker, red). Representative image shows microglial cells (green) and neurons (red). The percent of neurons in purified microglial cells was <2%.

(EPS)

**Acknowledgments**

We thank Dr. Andrea Kalinoski (University of Toledo Microscopy Imaging Core) for technical support. We also thank Drs. David Giovannucci, Richard Mooney, and John Wall for their technical advice.
**Author Contributions**

Conceived and designed the experiments: JP VM KH DK NC. Performed the experiments: VM JP YJ KC NC DK JE. Analyzed the data: VM JP YJ WJ. Contributed reagents/materials/analysis tools: JP NC DK KH. Wrote the paper: JP VM.

**References**

1. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014; 6(4):37. Epub 2014/07/16. doi:10.1186/alzrt269 alzrt269 [pii]. PMID:25024750; PubMed Central PMCID: PMC4095696.

2. Ghezzi L, Scarpini E, Galimberti D. Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7:1471–8. Epub 2013/12/20. doi:10.2147/DDDT.S41431 dddt-7-1471 [pii]. PMID:24353405; PubMed Central PMCID: PMC3862506.

3. Hogan DB. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry. 2014; 59(12):618–23. Epub 2015/02/24. PMID:25702360; PubMed Central PMCID: PMC4304580.

4. Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(9):89. Epub 2015/01/27. doi:10.1186/s13195-014-0089-7 89 [pii]. PMID:25621019; PubMed Central PMCID: PMC4304279.

5. Li Y, Hai S, Zhou Y, Dong BR. Cholinesterase inhibitors for rarer dementias associated with neurologic conditions. The Cochrane database of systematic reviews. 2015; 3:CD009444. doi:10.1002/ 14651858.CD009444.pub3 PMID: 25734590.

6. Faulkner MA. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease. Expert opinion on drug safety. 2014; 13(8):1055–69. doi:10.1517/14740338.2014.931369 PMID: 24962891.

7. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013; 80(19):1778–83. Epub 2013/02/08. doi:10.1212/ WNL.0b013e31828726f5 WNL.0b013e31828726f5 [pii]. PMID:23390181; PubMed Central PMCID: PMC3719424.

8. Iqbal K, Grundke-Iqbal I. Opportunities and challenges in developing Alzheimer disease therapeutics. Acta Neuropathol. 2011; 122(5):543–9. Epub 2011/10/01. doi:10.1007/s00401-011-0878-z PMID: 21959585.

9. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010; 9(7):702–16. Epub 2010/07/09. doi:10.1016/S1474-4422(10)70119-8 S1474-4422(10)70119-8 [pii]. PMID:20610346.

10. Selkoe DJ. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med. 2004; 140(8):627–38. Epub 2004/04/21. 140/8/627 [pii]. PMID:15096334.

11. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov. 2010; 9(5):543–9. Epub 2011/10/01. doi:10.1038/nrd2896 nrd2896 [pii]. PMID:21959585.

12. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004; 279(13):12876–82. Epub 2004/01/08. doi:10.1074/jbc.M311652200 M311652200 [pii]. PMID:14709552.

13. Blanchard J, Wanka L, Tung YC, Cardenas-Aguayo Mdel C, LaFerla FM, Iqbal K, et al. Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Abeta and tau pathologies in 3xTg-AD mice. Acta Neuropathol. 2010; 120(5):605–21. Epub 2010/08/11. doi:10.1007/s00401-010-0734-6 PMID: 20697724.

14. Burton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009; 106(32):13594–9. Epub 2009/07/28. doi:10.1073/pnas.0901420106 0901420106 [pii]. PMID:19633196; PubMed Central PMCID: PMC2715325.

15. Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, et al. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol. 2011; 123(1):133–51. Epub 2011/11/16. doi:10.1007/s00401-011-0908-x PMID:22083255; PubMed Central PMCID: PMC3389170.

16. Garcia P, Youssel I, Utvik JK, Florent-Bechard S, Barthelemy V, Malaplate-Armand C, et al. Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J Neurosci. 2010; 30(22):7516–27. Epub 2010/06/04. doi: 10.1523/ JNEUROSCI.4182-09.2010 30/22/7516 [pii]. PMID: 20519526.
17. Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A. 2011; 108(49):E1339–48. Epub 2011/11/02. doi: 10.1073/pnas.1102349108 1102349108 [pii]; PMID: 22042871; PubMed Central PMCID: PMC3241747.

18. Nagahara AH, Merrill DA, Coppola G, Tskada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009; 15(3):331–7. Epub 2009/02/10. doi: 10.1038/nm.1912 nm.1912 [pii]; PMID: 19198615; PubMed Central PMCID: PMC2883375.

19. Tiwari SK, Chaturvedi RK. Peptide therapeutics in neurodegenerative disorders. Curr Med Chem. 2014; 21(23):2610–31. Epub 2014/02/19. CMC-EPUB-59226 [pii]; PMID: 24533803.

20. Ciesler J, Sari Y. Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease. Open J Neurosci. 2013; 3. Epub 2013/06/26. 2 [pii]; PMID: 23795307; PubMed Central PMCID: PMC3686488.

21. Domanskiy A, Saarma M, Airavaara M. Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy. Hum Gene Ther. 2015; 26(8):550–9. Epub 2015/07/16. doi: 10.1089/hum.2015.065 PMID: 26176331.

22. Akagi M, Matsui N, Akae H, Hirashima N, Fukuishi N, Fukuyama Y, et al. Nonpeptide neurotrophic agents useful in the treatment of neurodegenerative diseases such as Alzheimer's disease. J Pharmacol Sci. 2015; 127(2):155–63. Epub 2015/03/03. doi: 10.1016/j.jphs.2014.12.015 S1347-8613(15)00004-3 [pii]; PMID: 25727952.

23. Yacila G, Sari Y. Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis. Curr Med Chem. 2014; 21(31):3883–93. Epub 2014/06/18. CMC-EPUB-60774 [pii]; PMID: 24934355; PubMed Central PMCID: PMC4182116.

24. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat Rev Neurosci. 2013; 14(6):401–16. Epub 2013/05/16. doi: 10.1038/nrn3505 [pii]; PMID: 23674053.

25. Rockenstein E, Ubhi K, Trejo M, Mante M, Patrick C, Apecechea M, et al. Cerebrolysin efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure. BMC Neurosci. 2013; 14:90. Epub 2013/07/23. doi: 10.1186/1471-2202-14-90 1471-2202-14-90 [pii]; PMID: 25047000; PubMed Central PMCID: PMC4122761.

26. Ruther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M. Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm. 2000; 107(7):815–29. Epub 2000/09/27. PMID: 11005546.

27. Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci. 2013; 33(39):15596–602. Epub 2013/09/27. doi: 10.1523/JNEUROSCI.3195-13.2013 33/39/15596 [pii]; PMID: 24068262; PubMed Central PMCID: PMC3782628.

28. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011; 10(3):209–19. Epub 2011/03/02. doi: 10.1038/nrd3366 nrd3366 [pii].

29. Barde YA, Davies AM, Johnson JE, Lindsay RM, Theoenn H. Brain derived neurotrophic factor. Prog Brain Res. 1987; 71:185–9. Epub 1987/01/01.

30. Longo FM, Massa SM. Neurotrophin receptor-based strategies for Alzheimer's disease. Curr Alzheimer Res. 2006; 3(2):167–9. Epub 2005/06/25. PMID: 15974914.

31. Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996; 36(2):280–6. Epub 1996/03/01. 0169328X9500250V [pii]; PMID: 8965648.

32. Molina-Holgado F, Doherty P, Williams G. Tandem repeat peptide strategy for the design of neurotrophic factor mimetics. CNS Neurol Drug Targets. 2008; 7(1):110–9. Epub 2008/02/22. PMID: 18289337.

33. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel N, GDNF. NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013; 138(2):155–75. Epub 2013/01/26. doi: 10.1016/j.pharmthera.2013.01.004 S0163-7258(13)00016-8 [pii]; PMID: 23348013.

34. Tereshchenko J, Maddinga E, Bahr M, Kugler S. Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson’s disease. Neurobiol Dis. 2014; 65:35–42. Epub 2014/01/21. doi: 10.1016/j.nbd.2014.01.009 S0969-986X(14)00023-0 [pii];

35. van Velthoven CT, Braccioli L, Willems H, Kavelaars A, Heijnen CJ. Therapeutic potential of genetically modified mesenchymal stem cells after neonatal hypoxic-ischemic brain damage. Mol Ther. 2013; 21(3):645–54. Epub 2013/11/01. mt2013260 [pii] doi: 10.1038/mt.2013.266 PMID: 24172866; PubMed Central PMCID: PMC3944339.
36. Minnich JE, Mann SL, Stock M, Stolzenbach KA, Mortell BM, Soderstrom KE, et al. Gial cell line-derived neurotrophic factor (GDNF) gene delivery protects cortical neurons from dying following a traumatic brain injury. Restor Neurol Neurosci. 2010; 28(3):293–309. Epub 2010/05/19. doi: 10.3233/RNN-2010-0528 61L80XW344217028 [pii]. PMID: 20479925.

37. Jafarieh O, Md S, Ali M, Baboota S, Sahni JK, Kumari B, et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm. 2014;1:1–8. Epub 2014/12/17. doi: 10.3109/03639045.2014.991400 PMID: 25496439.

38. Yemisci M, Caban S, Gursoy-Ozdemir Y, Lule S, Novoa-Carballal R, Riguera R, et al. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection. J Cereb Blood Flow Metab. 2014;35(3):489–75. Epub 2014/12/11. jcblm2014220 [pii] doi: 10.1038/jcbfm.2014.220 PMID: 25492116; PubMed Central PMCID: PMC4348388.

39. Popov M, Abu Hammad I, Bachar T, Grinberg S, Linder C, Stepensky D, et al. Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes. Eur J Pharm Biopharm. 2013; 85(3 Pt A):381–9. Epub 2013/06/25. doi: 10.1016/j.ejpb.2013.06.005 S0939-6411(13)00223-3 [pii]. PMID: 23791683.

40. Gao Y, Li C, Yin J, Shen J, Wang H, Wu Y, et al. Fucoidan, a sulfated polysaccharide from brown algae, improves cognitive impairment induced by infusion of Abeta peptide in rats. Environ Toxicol Pharmacol. 2012; 33(2):304–11. Epub 2012/02/04. S1382-6689(11)00208-0 [pii].

41. Chen Y, Zhao B, Huang X, Zhan J, Zhao Y, Zhou M, et al. Purification and neuroprotective effects of polysaccharides from Opuntia Milpa Alta in cultured cortical neurons. Int J Biol Macromol. 2011; 49(4):681–7. Epub 2011/07/19. doi: 10.1016/j.ijbiomac.2011.06.031 S0141-8130(11)00278-9 [pii]. PMID: 21763720.

42. Joodi G, Ansari N, Khodagholi F. Chitooligosaccharide-mediated neuroprotection is associated with modulation of Haps expression and reduction of MAPK phosphorylation. Int J Biol Macromol. 2011; 48(5):726–35. Epub 2011/03/02. doi: 10.1016/j.ijbiomac.2011.02.011 S0141-8130(11)00079-1 [pii]. PMID: 21356235.

43. Ho YS, Yu MS, Yang XF, So KF, Yuen WH, Chang RC. Neuroprotective effects of polysaccharides from wolfberry, the fruits of Lycium barbarum, against homocysteine-induced toxicity in rat cortical neurons. J Alzheimers Dis. 2010; 19(3):813–27. Epub 2010/02/17. doi: 10.3233/JAD-2010-12804W22311422618321 [pii]. PMID: 20157238.

44. Li G, Li Y, Tang Y, Zhang Y, Yin T, Xu H, et al. Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin. Int J Pharm. 2014; 471(1–2):234–44. Epub 2014/05/28. doi: 10.1016/j.ijpharm.2014.05.038 S0378-5173(14)00378-0 [pii]. PMID: 24861941.

45. Liebner R, Mathaes R, Meyer M, Hey T, Winter G, Besheer A. Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra. Eur J Pharm Biopharm. 2014; 87(2):378–85. Epub 2014/04/01. doi: 10.1016/j.ejpb.2014.03.010 S0939-6411(14)00087-3 [pii]. PMID: 24681396.

46. Sivasubramanian M, Lee JY, Kim KJ, Saravanakumar G, Kang YM, Park JH. Cyclodextrin-based nanocomplexes for sustained delivery of human growth hormone. J Nanosci Nanotechnol. 2013; 13(11):7306–11. Epub 2013/11/20. PMID: 24245248.

47. Miltenburg AM, Prohn M, van Kuik JH, Tiessen RG, de Kort M, Berg RJ. Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of Carbocarrier(R) insulin. Br J Clin Pharmacol. 2012; 75(5):1221–8. doi: 10.1111/j.1365-2125.2012.04460.x PMID: 22978318; PubMed Central PMCID: PMC3635593.

48. Agyare EK, Jaruszewski KM, Curran GL, Rosenberg JT, Grant SC, Lowe VJ, et al. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release. 2014; 185:121–9. Epub 2014/04/17. doi: 10.1016/j.jconrel.2014.04.010 S0168-3659(14)00214-4 [pii]. PMID: 24735640.

49. Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci. 2009; 29(44):13761–9. Epub 2009/11/06. doi: 10.1523/JNEUROSCI.4246-09.2009 29/44/13761 [pii]. PMID: 19889988.

50. Anderson DM, Brydon WG, Eastwood MA. The dietary effects of gellan gum in humans. Food Addit Contam. 1988; 5(3):237–49. Epub 1988/07/01. doi: 10.1080/0266238880937301 PMID: 2694053.

51. Woodbury ME, Ikazu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J Neuroimmune Pharmacol. 2013; 9(2):92–101. Epub 2013/09/24. doi: 10.1007/s11481-013-9501-5 PMID: 24057103; PubMed Central PMCID: PMC4109802.
Cambon K, Hansen SM, Venero C, Herrero AI, Skibo G, Berezin V, et al. A synthetic neural cell adhesion molecule mimetic peptide promotes synaptogenesis, enhances presynaptic function, and facilitates memory consolidation. J Neurosci. 2004; 24(17):4197–204. Epub 2004/04/30. doi: 10.1523/JNEUROSCI.0436-04.2004 24/17/4197 [pii]. PMID: 15115815.

Ronn LC, Doherty P, Holm A, Berezin V, Bock E. Neurite outgrowth induced by a synthetic peptide ligand of neural cell adhesion molecule requires fibroblast growth factor receptor activation. J Neurochem. 2000; 75(2):665–71. Epub 2000/07/19. PMID: 10899941.

Asai T, Wanaka A, Kato H, Masana Y, Seo M, Tohyama M. Differential expression of two members of FGF receptor gene family, FGFR-1 and FGFR-2 mRNA, in the adult rat central nervous system. Brain Res Mol Brain Res. 1993; 17(1–2):174–8. Epub 1993/01/01. PMID: 8381903.

Matsuo A, Tooyama I, Isobe S, Oomura Y, Akiguchi I, Hanai K, et al. Immunohistochemical localization in the rat brain of an epitope corresponding to the fibroblast growth factor receptor-1. Neuroscience. 1994; 60(1):49–66. Epub 1994/05/01. 0306-4522(94)00203-8 [pii]. PMID: 7519761.

Ford-Perriss M, Abud H, Murphy M. Fibroblast growth factors in the developing central nervous system. Clin Exp Pharmacol Physiol. 2001; 28(7):493–503. Epub 2001/06/26. cep3477 [pii]. PMID: 11422214.

Gill JC, Tsai PS. Expression of a dominant negative FGF receptor in developing GNRH1 neurons disrupts axon outgrowth and targeting to the median eminence. Biol Reprod. 2006; 74(3):463–72. Epub 2005/11/11. biolreprod.105.046904 [pii] PMID: 16280414.

Dionne CA, Crumley G, Bellot F, Kaplow JM, Searfoss G, Ruta M, et al. Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors. EMBO J. 1990; 9(9):2685–92. Epub 1990/09/01. PMID: 1697263; PubMed Central PMCID: PMC551973.

Mohammadi M, Olsen SK, Ibrahim OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005; 16(2):107–37. Epub 2005/05/03. S1359-6101(05)00088-0 [pii] doi: 10.1016/j.cytofgfr.2005.01.008 PMID: 15863029.

Ikegaya Y, Itsukaichi-Nishida Y, Ishihara M, Tanaka D, Matsuaki N. Distance of target search of isolated rat hippocampal neuron is about 150 microm. Neuroscience. 2000; 97(2):215–5. Epub 2000/05/09. S0306-4522(00)00081-8 [pii]. PMID: 10799753.

Katsuki H, Itsukaichi Y, Matsuaki N. Distinct signaling pathways involved in multiple effects of basic fibroblast growth factor on cultured rat hippocampal neurons. Brain Res. 2000; 885(2):240–50. Epub 2000/12/05. S0006-8993(00)02953-X [pii]. PMID: 11102578.

Stopa EG, Gonzalez AM, Chorsky R, Corona RJ, Alvarez J, Bird ED, et al. Basic fibroblast growth factor in Alzheimer's disease. Biochem Biophys Res Commun. 1990; 171(2):690–6. Epub 1990/09/14. 0006-291X(90)91203-8 [pii]. PMID: 2403357.

Baskin F, Smith GM, Fosmire JA, Rosenberg RN. Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures. J Neurol Sci. 1997; 148(1):15–20. Epub 1997/03/25. S0022-510X(96)03535-X [pii]. PMID: 9125385.

Liu X, Zhu XZ. Roles of p53, c-Myc, Bcl-2, Bax and caspases in glutamate-induced neuronal apoptosis and the possible neuroprotective mechanism of basic fibroblast growth factor. Brain Res Mol Brain Res. 1999; 71(2):210–6. Epub 1999/10/16. S0926-6573(99)00186-2 [pii]. PMID: 10521579.

Feng C, Zhang C, Shao X, Liu Q, Qian Y, Feng L, et al. Enhancement of nose-to-brain delivery of basic fibroblast growth factor using novel lentivirus vector for improving rat memory impairments induced by co-injection of beta-amyloid and ibotenic acid into the bilateral hippocampus. Int J Pharm. 2012; 423(2):226–34. Epub 2011/12/24. doi: 10.1016/j.ijpharm.2011.12.008 S0378-5173(11)01133-1 [pii]. PMID: 22193058.

Graham BM, Richardson R. Early-life exposure to fibroblast growth factor-2 facilitates context-dependent long-term memory in developing rats. Behav Neurosci. 2010; 124(3):337–45. Epub 2010/06/10. 10.3758/0890-3378-124(3)337 [pii]. PMID: 20528078.

Noshita T, Murayama N, Oka T, Ogino R, Nakamura S, Inoue T. Effect of bFGF on neuronal damage induced by sequential treatment of amyloid beta and excitatory amino acid in vitro and in vivo. Eur J Pharmacol. 2012; 695(1–3):76–82. Epub 2012/10/03. doi: 10.1016/j.ejphar.2012.09.020 S0014-2999(12)00794-7 [pii]. PMID: 23026373.

Sun D, Bullock MR, McGinn MJ, Zhou Z, Altememi N, Hagood S, et al. Basic fibroblast growth factor-enhanced neurogenesis contributes to cognitive recovery in rats following traumatic brain injury. Exp Neurol. 2009; 216(1):56–65. Epub 2008/12/23. doi: 10.1016/j.expneurol.2008.11.011 S0014-4886(08)00435-4 [pii]. PMID: 19100261; PubMed Central PMCID: PMC2707259.

Casey BJ, Somerville LH, Gottlib IH, Ayduk O, Franklin NT, Askrend MK, et al. Behavioral and neural correlates of delay of gratification 40 years later: Proc. Natl. Acad. Sci. U.S.A. 2011, Vol 108 No. 36:14998–5003. Ann Neurosci. 2012; 19(1):27–8. Epub 2012/01/01. 180407 [pii]. PMID: 25205959; PubMed Central PMCID: PMC4117069.
70. Katsouri L, Ashraf A, Birch AM, Lee KK, Mirzaei N, Sastre M. Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice. Neurobiol Aging. 2015; 36(2):821–31. Epub 2014/12/03. doi: 10.1016/j.neurobiolaging.2014.10.004. PMID: 25457554.

71. Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, et al. Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. J Clin Pharmacol. 2001; 41(4):378–85. Epub 2001/04/18. PMID: 11304894.

72. Doherty P, Walsh FS. CAM-FGF receptor interactions: a model for axonal growth. Mol Cell Neurosci. 1996; 8(2–3):99–111. Epub 1996/01/01. S1044-7431(96)90049-4 [pii] doi: 10.1006/mcne.1996.0049. PMID: 8918827.

73. Kolkova K, Novitskaya V, Pedersen N, Berezin V, Bock E. Neural cell adhesion molecule-stimulated neurite outgrowth depends on activation of protein kinase C and the Ras-mitogen-activated protein kinase pathway. J Neurosci. 2000; 20(6):2238–46. Epub 2000/03/08. PMID: 10704499.

74. Kiselev VV, Skladchikova G, Hinsby AM, Jensen PH, Kulahin N, Soroka V, et al. Structural basis for a direct interaction between FGFR1 and NCAM and evidence for a regulatory role of ATP. Structure. 2003; 11(6):691–701. Epub 2003/06/07. S0969212603000960 [pii]. PMID: 12791257.

75. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005; 16(2):233–47. Epub 2005/05/03. S1359-6101(05)00099-2 [pii] doi: 10.1016/j.cytogfr.2005.01.007. PMID: 15860308.

76. Chen Y, Li S, Berezin V, Bock E. The fibroblast growth factor receptor (FGFR) agonist FGF1 and the neural cell adhesion molecule-derived peptide FGL activate FGFR substrate Zathpha differently. J Neurosci Res. 2010; 88(9):1882–9. Epub 2010/02/23. doi: 10.1002/jnr.22374. PMID: 20175207.

77. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal. 2004; 16(11):1211–9. Epub 2004/09/01. doi: 10.1016/j.cellsig.2004.05.001. S0898662104000804 [pii]. PMID: 15337521.

78. Walmod PS, Kolkova K, Berezin V, Bock E. Zippers make signals: NCAM-mediated molecular interactions and signal transduction. Neurochem Res. 2004; 29(11):2015–35. Epub 2005/01/25. PMID: 15662836.

79. Neiendam JL, Kohler LB, Christensen C, Li S, Pedersen MV, Dittevsen DK, et al. An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. J Neurochem. 2004; 91(4):920–35. doi: 10.1111/j.1471-4159.2004.02779.x. PMID: 15525346.

80. Knafo S, Venero C, Sanchez-Puelles C, Pereda-Perez I, Franco A, Sandi C, et al. Facilitation of AMPA receptor synaptic delivery as a molecular mechanism for cognitive enhancement. PLoS Biol. 2012; 10(2):e1001282. Epub 2012/02/01. doi: 10.1371/journal.pbio.1001282. PBIOL0GY-D-11-00513 [pii]. PMID: 22363206. PubMed Central PMCID: PMC3283560.

81. Secher T, Novitskaya V, Berezin V, Bock E, Glenthoj B, Klementiev B. A neural cell adhesion molecule-derived fibroblast growth factor receptor agonist, the FGL-peptide, promotes early postnatal sensorimotor development and enhances social memory retention. Neuroscience. 2006; 141(3):1289–99. Epub 2006/06/21. S0306-4522(06)00607-9 [pii] doi: 10.1016/j.neuroscience.2006.04.039. PMID: 16784819.

82. Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmitrieva O, Pakkenberg B, et al. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35. Neuroscience. 2007; 145(1):209–24. Epub 2007/01/16. S0306-4522(06)01656-3 [pii] PMID: 17223274.

83. Skibo GG, Lushnikova IV, Voronin KY, Dmitrieva O, Novikova T, Klementiev B, et al. A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo. Eur J Neurosci. 2005; 22(7):1589–96. Epub 2005/07/21. S0969-2126(05)00096-0 [pii]. PMID: 15784819.

84. Bhat RV, Budd Haebeliein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem. 2004; 89(6):1313–9. Epub 2004/06/11. doi: 10.1111/j.1471-4159.2004.02422.x. JNC2422 [pii]. PMID: 15189333.

85. Anand R, Seiberling M, Kamchoua T, Pokorny R. Tolerability, safety and pharmacokinetics of the FGFR agonist FGF1 and the FGFR antagonist FGF2 in a phase I trial in coronary artery disease. J Clin Pharmacol. 2001; 41(4):378–85. Epub 2001/04/18. PMID: 11304894.

86. Park JJ, Cawley NX, Loh YP. A bi-directional carboxypeptidase E-driven transport mechanism controls BDNF vesicle homeostasis in hippocampal neurons. Mol Cell Neurosci. 2008; 39(1):63–73. Epub 2008/06/25. S1044-7431(08)00138-5 [pii] doi: 10.1016/j.mcn.2008.05.016. PMID: 18573344. PubMed Central PMCID: PMC2606928.
87. Masuko T, Minami A, Iwasaki N, Majima T, Nishimura S, Lee YC. Carbohydrate analysis by a phenolsulfuric acid method in microneate format. Anal Biochem. 2005; 339(1):69–72. Epub 2005/03/16. S0003-2697(04)00952-2 [pii] doi: 10.1016/j.ab.2004.12.001 PMID: 15766712.

88. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer’s disease. Neurobiol Aging. 1997; 18(5):457–61. Epub 1997/12/09. S0197-4580(97)00108-5 [pii] PMID: 9390770.

89. McGrath LT, McGleenon BM, Brennan S, McColl D, Mc IS, Passmore AP. Increased oxidative stress in Alzheimer’s disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM. 2001; 94(9):485–90. Epub 2001/08/31. PMID: 11528012.

90. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta. 2011; 1812(11):1359–70. Epub 2011/08/30. doi: 10.1016/j.bbadis.2011.08.005 S0925-4439(11)00187-6 [pii] PMID: 21871956; PubMed Central PMCID: PMC3185172.

91. Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer’s disease: implications for synaptic damage and cognitive decline. J Alzheimers Dis. 2010; 20 Suppl 2:S499–512. Epub 2010/04/24. doi: 10.3233/JAD-2010-100504 5766WJ087272J666 [pii] PMID: 20419347; PubMed Central PMCID: PMC3059092.

92. Gulden M, Jess A, Kammann J, Maser E, Seibert H. Cytotoxic potency of H2O2 in cell cultures: impact of cell concentration and exposure time. Free Radic Biol Med. 2010; 49(8):1298–305. Epub 2010/08/03. S0891-5849(10)00447-7 [pii] doi: 10.1016/j.freeradbiomed.2010.07.015 PMID: 20673847.

93. Wang ZJ, Liang CL, Li GM, Yu CY, Yin M. Stearic acid protects primary cultured cortical neurons from hydrogen peroxide and hypoxia-ischemia. J Neurochem. 2004; 91(5):1164–70. Epub 2004/12/01. JNC5786WJ087254.00052.x PMID: 15365055.

94. Wu B, Kitagawa K, Zhang NY, Liu B, Inagaki C. Pathophysiological concentrations of amyloid beta peptide directly inhibit rat brain and recombinant human type II phosphatidylinositol 4-kinase activity. J Neurochem. 2004; 91(5):1164–70. Epub 2004/12/01. JNC5786WJ087254.00052.x PMID: 15365055.
125. Liu R, Wang JZ. Protein phosphatase 2A in Alzheimer's disease. Pathophysiology. 2009; 16(4):273

124. Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem. 2003; 278(1):187–93. doi: 10.1074/jbc.M206236200 PMID: 1240305.

123. Fagan AM, Holtzman DM. Cerebrospinal fluid biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006; 27(3):394–401. doi: 10.1016/j.neurobiolaging.2005.07.003 PMID: 16125823.

122. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006; 27(3):394–401. doi: 10.1016/j.neurobiolaging.2005.07.003 PMID: 16125823.

121. Saura CA, Valero J. The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Neurotherapeutics. 2015; 12(1):29–39. doi: 10.1007/s13311-014-0327-5 PMID: 25575647; PubMed Central PMCID: PMCPMC4322064.

120. Zechini S, Cavallaro U. Neural cell adhesion molecule in cancer: expression and mechanisms. Adv Exp Med Biol. 2010; 663:319–33. doi: 10.1007/978-1-4419-1170-4_20 PMID: 20107031.

119. Sperling MR, Haas KF, Krauss G, Seif Eddeine H, Henney HR 3rd, Rabinowicz AL, et al. Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy. Epilepsia. 2014; 55(10):1544–56. doi: 10.1111/epi.12755 PMID: 24636461.

118. Barco A, Marie H. Genetic approaches to investigate the role of CREB in neuronal plasticity and memory. Mol Neurobiol. 2011; 44(3):330–49. doi: 10.1007/s12035-011-8209-x PMID: 21948060.

117. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005; 45(5):675–88. Epub 2005/03/08. S0896-6273(05)00078-4 [pii] doi: 10.1016/neuron.2005.01.040 PMID: 15748844.

116. Jirkof P. Burrowing and nest building behavior as indicators of well-being in mice. J Neurosci Methods. 2010; 186(1):60–6. doi:10.1016/j.jneumeth.2010.04.002 PMID: 20413914.

115. Sivanesan S, Tan A, Rajadas J. Pathogenesis of Abeta oligomers in synaptic failure. Curr Alzheimer Res. 2012; 10(3):316–23. Epub 2012/10/06. CAR-EPUB-20121002-2 [pii] PMID: 23036017.

114. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006; 27(3):394–401. doi: 10.1016/j.neurobiolaging.2005.07.003 PMID: 16125823.

113. Teich AF, Nicholls RE, Puzzo D, Fiorito J, Purgatorio R, Fa M, et al. Synaptic therapy in Alzheimer's disease: a CREB-centric approach. Neurotherapeutics. 2015; 12(1):29–39. doi: 10.1007/s13311-014-0327-5 PMID: 25575647; PubMed Central PMCID: PMCPMC4322064.

112. Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, et al. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008; 1216:92–103. Epub 2008/05/20. doi: 10.1016/j.brainres.2008.03.079 S0006-8993(08)00816-0 [pii] PMID: 18486110.

111. Torres-Lista V, Gimenez-Llort L. Impairment of nesting behaviour in 3xTg-AD mice. Behav Brain Res. 2013; 247:153–7. doi: 10.1016/j.bbr.2013.03.021 PMID: 23523959.

110. Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, et al. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. Eur Neuropsychopharmacol. 2014; 24(6):846–55. Epub 2014/03/19. doi:10.1016/j.euroneuro.2014.02.001 S0924-977X(14)00055-8 [pii]. PMID: 24636461.

109. Clinton LK, Billings LM, Green KN, Caccamo A, Nao J, Oddo S, et al. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis. 2007; 28(1):76–82. Epub 2007/07/31. S0969-9616(07)00135-0 [pii] doi: 10.1016/nbd.2007.06.013 PMID: 17659878; PubMed Central PMCID: PMCP2756084.

108. Carroll JC, Rosario ER, Kreimer S, Villamagna A, Gentzsch E, Hamada K, et al. Mitochondrial Number. J Alzheimers Dis. 2013. Epub 2013/10/24. 673K83H10156476R [pii] doi: 10.3233/JAD-130680 PMID: 24150104.
126. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, et al. Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci. 2007; 27(45):12211–20. doi: 10.1523/JNEUROSCI.3321-07.2007 PMID: 17989287.

127. Fang X, Yu SX, Lu Y, Bast RC Jr., Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 2000; 97(22):11960–5. doi: 10.1073/pnas.220413597 PMID: 11035810; PubMed Central PMCID: PMCPMC17277.

128. Qian W, Shi J, Yin X, Iqbal K, Grundke-Iqbal I, Gong CX, et al. PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis. 2010; 19(4):1221–9. doi: 10.3233/JAD-2010-1317 PMID: 20308788.

129. Li T, Hawkes C, Qureshi HY, Kar S, Paudel HK. Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry. 2006; 45(10):3134–45. doi: 10.1021/bi051635j PMID: 16519508.

130. Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 2000; 485(1):87–93. PMID: 11086171.